PARSIPPANY, N.J. and REYKJAVÍK, Iceland, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Alvotech (NASDAQ: ...

Teva Pharmaceuticals and Alvotech have announced that the US Food and Drug Administration (FDA) has approved the Selarsdi (ustekinumab-aekn) injection as interchangeable with reference biologic ...

CSPC PHARMA (01093.HK) announced that the Groups self-developed ustekinumab injection, marketed under the brand name Enyike, ...

A biosimilar version of the multipurpose biologic drug ustekinumab has been approved by the FDA and can be swapped interchangeably with the original product sold as Stelara. The new version carries ...

Patients may now switch between Otulfi and Stelara without requiring a prescription change from a health care provider. The Food and Drug Administration (FDA) has designated Otulfi ® (ustekinumab-aauz ...

The approval was based on a totality of evidence, including data from a phase 3 study (ClinicalTrials.gov Identifier: NCT04967508) that compared the efficacy and safety of Pyzchiva to the reference ...

Medicare Part B does not typically cover ustekinumab (Stelara) because it is a self-administered drug, but Medicare Part D plans provide cover. Why does Part B not offer coverage? Medicare Part B is ...

Please provide your email address to receive an email when new articles are posted on . Four biosimilars for Stelara have launched in the United States this year following legal settlements with the ...